Across TCGA pan-cancer cohorts, DDX3X Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated DDX3X data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher DDX3X Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DDX3X expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.
THYM, LGG, and LUSC are the cancer types where DDX3X Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.